XTX Topco Ltd Increases Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

XTX Topco Ltd raised its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 382.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 60,586 shares of the biotechnology company’s stock after purchasing an additional 48,033 shares during the period. XTX Topco Ltd’s holdings in CytomX Therapeutics were worth $74,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. SG Americas Securities LLC purchased a new stake in shares of CytomX Therapeutics during the first quarter valued at $57,000. Susquehanna Fundamental Investments LLC bought a new position in CytomX Therapeutics during the 1st quarter valued at about $124,000. Candriam S.C.A. purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at about $256,000. Congress Park Capital LLC grew its stake in shares of CytomX Therapeutics by 393.3% in the second quarter. Congress Park Capital LLC now owns 1,153,220 shares of the biotechnology company’s stock worth $1,407,000 after acquiring an additional 919,420 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of CytomX Therapeutics by 206.0% during the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock valued at $1,511,000 after purchasing an additional 833,825 shares during the last quarter. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

Shares of CTMX stock opened at $1.15 on Wednesday. CytomX Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $5.85. The firm has a fifty day moving average price of $1.23 and a 200-day moving average price of $1.65. The company has a market cap of $89.61 million, a price-to-earnings ratio of 5.75 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. The company had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $21.79 million. During the same quarter in the previous year, the company earned ($0.02) EPS. Equities research analysts expect that CytomX Therapeutics, Inc. will post -0.2 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on CTMX shares. HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, September 13th. StockNews.com downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 17th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $5.77.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.